TILs Outperform Ipilimumab in Melanoma.

Cancer discovery 2023 Feb 06

filter terms:

all
biogroup
compound
gene and proteins
tissue
show more »
show less «

The first phase III study of tumor-infiltrating lymphocytes in melanoma shows that the cells are more effective than ipilimumab. Compared with the CTLA4 inhibitor, tumor-infiltrating lymphocytes yielded a higher objective response rate and longer progression-free and overall survival. ©2023 American Association for Cancer Research.